ZYME vs. SVRA, SLN, LYEL, MLYS, PHAR, AVBP, ORIC, PHAT, STOK, and CALT
Should you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Savara (SVRA), Silence Therapeutics (SLN), Lyell Immunopharma (LYEL), Mineralys Therapeutics (MLYS), Pharming Group (PHAR), ArriVent BioPharma (AVBP), ORIC Pharmaceuticals (ORIC), Phathom Pharmaceuticals (PHAT), Stoke Therapeutics (STOK), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical preparations" industry.
Savara (NASDAQ:SVRA) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, community ranking, profitability, analyst recommendations, risk, dividends and earnings.
87.9% of Savara shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 4.6% of Savara shares are owned by insiders. Comparatively, 1.2% of Zymeworks shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Savara currently has a consensus price target of $8.80, suggesting a potential upside of 96.43%. Zymeworks has a consensus price target of $12.67, suggesting a potential upside of 38.89%. Given Zymeworks' stronger consensus rating and higher probable upside, equities research analysts clearly believe Savara is more favorable than Zymeworks.
Savara has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Zymeworks has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.
In the previous week, Savara had 18 more articles in the media than Zymeworks. MarketBeat recorded 19 mentions for Savara and 1 mentions for Zymeworks. Savara's average media sentiment score of 0.13 beat Zymeworks' score of -0.04 indicating that Zymeworks is being referred to more favorably in the news media.
Savara received 1 more outperform votes than Zymeworks when rated by MarketBeat users. However, 68.59% of users gave Zymeworks an outperform vote while only 65.98% of users gave Savara an outperform vote.
Savara has higher earnings, but lower revenue than Zymeworks. Savara is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.
Savara has a net margin of 0.00% compared to Savara's net margin of -249.63%. Savara's return on equity of -28.37% beat Zymeworks' return on equity.
Summary
Savara beats Zymeworks on 9 of the 17 factors compared between the two stocks.
Get Zymeworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zymeworks Competitors List
Related Companies and Tools
